Evenamide’s Road Ahead: Newron Execs Hit Conference Circuit to Address FDA Pause and Chart a Path to Q4 2026 Data

Newron Pharmaceuticals is sending its top brass to two investor conferences in June — a move that on the surface looks like standard corporate schmoozing. But given the recent FDA halt on new patient enrollment at US sites for the Phase III ENIGMA-TRS 2 study, these roadshow appearances carry more weight than usual.

CEO Stefan Weber and CFO Roberto Galli will first take the stage at the Jefferies Global Healthcare Conference in New York from 2–4 June, with a company presentation scheduled for 4 June. They will then join the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference on 15–16 June for virtual meetings and one-on-one sessions with institutional investors. A recorded presentation will be available to registered participants from 15 June. The agenda does not include new clinical data or regulatory decisions — the goal is access, clarity, and reassurance.

The backdrop to these meetings is the FDA’s decision in late April to pause enrollment of new patients at US investigational sites for ENIGMA-TRS 2. The trigger was the sudden death of a study participant at a site outside the United States. The investigator classified the event as not treatment-related, and an independent safety committee recommended that the trials continue as planned. Still, the enrollment stop remains a live issue and the central talking point for investors: when will US recruitment resume, and how does the status differ from the parallel ENIGMA-TRS 1 study?

ENIGMA-TRS 1, a 52-week international Phase III trial targeting at least 600 patients across 21 countries, is unaffected and continues to run. More than 400 patients have already been enrolled. ENIGMA-TRS 2, which aims to enrol roughly 400 patients in the US, Argentina, India, and other countries, has regulatory clearance in Argentina and India, while approvals in Colombia and Malaysia are in the final stages. The FDA hold applies only to US sites.

Should investors sell immediately? Or is it worth buying Newron SpA?

Evenamide, Newron’s lead drug candidate for treatment-resistant schizophrenia, remains the company’s sole value driver. The molecule modulates excessive glutamatergic activity in the brain and has shown increasing and sustained symptom improvement in earlier studies. Beyond the ENIGMA programme, partner EA Pharma (part of the Eisai group) launched a Phase III study with Evenamide in Japan in January 2026, holding rights for development, manufacturing, and marketing in Japan and select Asian markets.

The next major catalyst for Newron is the release of data from the 12-week primary endpoint of ENIGMA-TRS 2, which the company still expects in the fourth quarter of 2026. That timeline has not changed despite the FDA pause, and it will be the real test of whether Evenamide can deliver on its clinical promise.

Newron’s financial position has improved markedly. At end-2025, the company held €28.9 million in cash and short-term financial assets, up from €9.8 million at the start of the year. In February 2026, it closed a subscription agreement for the issuance of new shares to existing and new investors in Europe and Asia, with a potential gross proceeds of up to €38 million. In March, Newron also amended the terms of its financing agreement with the European Investment Bank dating back to 2018, extending the maturity of all outstanding tranches to 28 June 2028. The available funds are expected to cover development programmes and operating costs well into 2027.

Newron SpA at a turning point? This analysis reveals what investors need to know now.

The financial and liquidity buffer gives management some breathing room, but the market remains sceptical. Newron reported a net loss of €13.2 million for 2025 on revenues of €19.1 million — the investment case hinges entirely on clinical milestones. The stock closed at €15.80 on Thursday, up 12.06% over the past month but down 40.60% year-to-date. From the January high of €32.95, the shares have more than halved, though they still trade at more than double the 52-week low seen last summer.

The June conferences offer Newron’s management a platform to contextualise the FDA hiccup, clarify recruitment timelines, and reinforce the unchanged data timeline. But without fresh regulatory decisions or trial results, the share price is likely to remain tethered to perceived risks around the Phase III programme. The real inflection point comes in Q4 2026 — until then, the roadshows are a communication exercise, not a pivot.

Ad

Newron SpA Stock: New Analysis - 29 May

Fresh Newron SpA information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Newron SpA analysis...

en | IT0004147952 | EVENAMIDE’S | boerse | 69442668 |